Clinical Significance Of The Expression Of P53,c-erbb2,mrp In Resected Non-small-cell Lung Cancer

Aim:To investigate prognostic and predictive importance of of P53,c-erbB2,MRP expression and its relationship with clinicopathologic parameters in non-small-cell lung cancer (NSCLC).Method:Detection of P53,c-erbB2,MRP protein expression in 152 tumor samples from resected primary NSCLCs was performed by immunohistochemical staining using a polyclonal antibody.The correlation of proteins, survival and clinicopathologic parameters was investigated in 152 patients undergoing potentially curative surgery.Results:The positive rate of P53,c-erbB2,MRP expression was 53.9%(82/152), 44.1%(67/152) and 43.4%(66/152) respectively. There were significantly relationship of P53 positive expression with gender, tumor differntiation, TNM stage and lymph metastasis respectively (P<0.05), but no relationship of c-erbB2 expression with clinicopathologic parameters in NSCLC. MRP positive rate (67.6%) in adenocarcinoma was significantly higher than (33.0%) in squamous-cell carcinomas (P<0.05). Overall survival was significantly correlated with the co-overexpression of P53, c-erbB2 and MRP proteins. Overall survival rate in 1,2,3 years with the co-positive were respectively 72.6%,54.8% and 32.2%, lower than co-negative 92.1%,78.5% and 63.4% (P=0.02,0.01 or 0.00); co-positive lower than co-negative by surgery alone (P<0.05), and that co-positive with c-erbB2 and MRP lower than co-negative by surgery plus chemotherapy(P=0.01). It was showed by Cox's model analysis that c-erbB2 expression or cell differentiation was an independent prognostic factor in patients with completely resected NSCLC.Conclutions:These findings clearly suggest that the specific oncoprotein co-overexpression is correlated with NSCLC patients' overall survival. Detection of P53, c-erbB2 and MRP co-expression may be a useful predictive indicator of prognosis. C-erbB2 expression is an independent prognostic factor, and may provide a useful predictive indicator of response to chemotherapy or molecular targeted therapies with c-erbB2 inhibitors in NSCLC.